HLA-A*02:01 allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of the HLA variation in PDAC
Alberto Langtry,Raul Rabadan,Lola Alonso,Casper van Eijck,Teresa Macarulla,Rita Lawlor,Alfredo Carrato,Rafael Alvarez-Gallego,Mar Iglesias,Xavier Molero,J Matthias Lohr,Christopher Michalski,Jose Perea,Michael ORorke,Victor Barber,Adonina Tardon,Antoni Farre,Luis Munoz-Bellvis,Tatjana Crnogorac-Jurcevic,Enrique Dominguez-Munoz,Thomas Gress,William Greenhalf,Linda Sharp,Sergio Sabroso-Lasa,Ioan Filip,Gaby Strijk,Florian Castet,Joaquim Balsells,Eithne Costello,Jorg Kleeff,Bo Kong,Josefina Mora,Damian ODriscoll,Aldo Scarpa,Weimin Ye,Francisco X. Real,Nuria Malats,Evangelina Lopez de Maturana
DOI: https://doi.org/10.1101/2024.08.29.24312704
2024-08-29
Abstract:Genetic susceptibility loci are associated with PDAC risk and survival, but the impact of germline HLA region variation remains largely unexplored. This study examined HLA I-II alleles within the PanGenEU study and validated our findings using external datasets (UK Biobank, TCGA, PAN-NGS trial, and Caris trial). HLA-A*02:01and HLA-B*49 alleles were linked to a decreased risk of PDAC, whereas HLA-B*39, HLA-DPB1*04, and HLA-A*26:01 were directly associated with increased risk. PDAC patients carrying the HLA-A*02:01 allele also showed lower mortality rates, with the effect being more pronounced in those with KRASG12V mutations, pointing to a host*tumor genetic interaction. This research highlights HLA-A*02:01, found in 20% of Europeans, as a marker for reduced PDAC risk and mortality, especially in KRASG12V mutated tumors.